Complementation of Brucella abortus RB51 with a Functional wboA Gene Results in O-Antigen Synthesis and Enhanced Vaccine Efficacy but No Change in Rough Phenotype and Attenuation
VEMULAPALLI, R, YONGQUN HE, BUCCOLO, L. S, BOYLE, S. M, SRIRANGANATHAN, N, SCHURIG, G. G
Published in Infection and Immunity (01.07.2000)
Published in Infection and Immunity (01.07.2000)
Get full text
Journal Article
Berberine associated to SGLT2i Dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to Trastuzumab through reduction of AGEs and IL-6 and induction of pAMPK
Maurea, N, Buccolo, S, Iovine, M, Maurea, C, Paccone, A, Quagliariello, V
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels
Bonelli, A., Quagliariello, V., Buccolo, S., Maurea, F., Paccone, A., Maurea, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
15P The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways
Buccolo, S., Quagliariello, V., Maurea, C., Berretta, M., Paccone, A., De Laurentiis, M., Maurea, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Oxidized Low-Density Lipoproteins increases nivolumab-induced cardiotoxicity through TLR4/NF-KB and NLRP3 pathways
Quagliariello, V, Bonelli, A, Paccone, A, Buccolo, S, Iovine, M, Botti, G, Maurea, N
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article
Evolocumab, a PCSK9 inhibitor, co-incubated with doxorubicin and trastuzumab reduces death of cardiomyocytes through reduction of MyD88-NLRP3-NF-kB-mTORC1
Quagliariello, V, Bonelli, A, Paccone, A, Buccolo, S, Iovine, M, Conforti, G, Botti, G, Maurea, N
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article
6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways
Quagliariello, V., Buccolo, S., Iovine, M., Cerrone, F., Paccone, A., Maurea, N.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Sacubitril-valsartan activates pAMPK and reduces NLRP3, MyD88, cytokines/growth factors and DAMPs in doxorubicin-treated mice improving longitudinal strain and ejection fraction
Maurea, N, Buccolo, S, Iovine, M, Paccone, A, Luciano, A, Barbieri, A, Palma, G, Maurea, C, Quagliariello, V
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
14P Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction
Caronna, A., Quagliariello, V., Buccolo, S., Maurea, F., Luciano, A., Barbieri, A., Palma, G., Paccone, A., Maurea, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
P131 LOW DOSES OF ADVANCED GLYCATION END–PRODUCTS AND FRUCTOSILATION PRODUCTS PROMOTES PREMATURE CELL DEATH OF HUMAN CARDIAC CELLS EXPOSED TO DOXORUBICIN VIA ACTIVATION OF NLRP3, MYD88 AND P53 DOWNREGULATION
Quagliariello, V, Paccone, A, Iovine, M, Buccolo, S, Maurea, N
Published in European heart journal supplements (18.05.2022)
Published in European heart journal supplements (18.05.2022)
Get full text
Journal Article
C49 SACUBITRIL–VALSARTAN IMPROVES LONGITUDINAL STRAIN AND EJECTION FRACTION IN MICE TREATED WITH DOXORUBICIN THROUGH NLRP3, MYD88 PATHWAYS RESULTING IN A REDUCTION OF MYOCARDIAL IL–1Β, IL–6, TNF–Α, G–CSF AND GM–CSF LEVELS
Quagliariello, V, Iovine, M, Buccolo, S, Paccone, A, Maurea, N
Published in European heart journal supplements (18.05.2022)
Published in European heart journal supplements (18.05.2022)
Get full text
Journal Article
P142 PALMITOYLETHANOLAMIDE (PEA) REDUCES INFLAMMATION IN HUMAN CARDIOMYOCYTES AND VASCULAR ENDOTHELIAL CELLS EXPOSED TO DOXORUBICIN AND ANTI–HER2 MONOCLONAL ANTIBODY THROUGH PPAR–Α AND NLRP3–RELATED PATHWAYS
Quagliariello, V, Buccolo, S, Iovine, M, Paccone, A, Maurea, N
Published in European heart journal supplements (18.05.2022)
Published in European heart journal supplements (18.05.2022)
Get full text
Journal Article
P221 DAPAGLIFLOZIN ASSOCIATED TO SACUBITRIL/VALSARTAN EXERTS ADDITIVE CARDIOPROTECTION IN HUMAN CARDIOMYOCYTES EXPOSED TO DOXORUBICIN AND TRASTUZUMAB THROUGH MYD88, NLRP3 MEDIATED PATHWAYS AND IMPROVEMENT OF MYTOGENESIS
Quagliariello, V, Iovine, M, Buccolo, S, Maurea, N
Published in European heart journal supplements (18.05.2022)
Published in European heart journal supplements (18.05.2022)
Get full text
Journal Article
The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3
Quagliariello, V, Bonelli, A, Paccone, A, Buccolo, S, Iovine, M, Rea, D, Cerrone, F, Botti, G, Maurea, N
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article
TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines
Maurea, N, Quagliariello, V, Bonelli, A, Paccone, A, Conforti, G, Caronna, A, Buccolo, S, Iovine, M, Cerrone, F, Botti, G
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article
Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue
Maurea, N, De Lorenzo, C, Passariello, M, Iovine, M, Buccolo, S, Di Mauro, A, Cipullo, C, Paccone, A, Maurea, F, Caronna, A, Quagliariello, V
Published in European heart journal (03.10.2022)
Published in European heart journal (03.10.2022)
Get full text
Journal Article
36P Short-term immune check-point inhibitor treatment reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and serum IL-1, IL-2 and IL-6 levels
Paccone, A., Quagliariello, V., Passariello, M., Buccolo, S., Barbieri, A., Palma, G., Luciano, A., Di Mauro, A., Cipullo, C., De Lorenzo, C., Maurea, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
Ipilimumab and Nivolumab exertes cardiotoxic and pro-fibrotic effects in mice through the overexpression of NLRP3 inflammasome, chemokines and leukotrienes
Quagliariello, V, Passariello, M, Rea, D, Barbieri, A, Buccolo, S, Iovine, M, Bonelli, A, Caronna, A, Botti, G, De Lorenzo, C, Maurea, N
Published in European heart journal (12.10.2021)
Published in European heart journal (12.10.2021)
Get full text
Journal Article